Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2016, Article ID 5163789, 13 pages
http://dx.doi.org/10.1155/2016/5163789
Review Article

Acute Kidney Injury in Hematopoietic Stem Cell Transplantation: A Review

1Akron Nephrology Associates/Akron General Cleveland Clinic, Akron, OH, USA
2Department of Internal Medicine, Akron General Cleveland Clinic, Akron, OH, USA
3Onco-Hospitalist, Beth Israel Deaconness Medical Center, Boston, MA, USA
4Department Hematology/Medical Oncology, Akron General Cleveland Clinic, Akron, OH, USA
5Department of Nephrology/Internal Medicine, Akron General Cleveland Clinic, Akron, OH, USA

Received 20 August 2016; Revised 4 October 2016; Accepted 11 October 2016

Academic Editor: Kazunari Kaneko

Copyright © 2016 Vinod Krishnappa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Sawinski, “The kidney effects of hematopoietic stem cell transplantation,” Advances in Chronic Kidney Disease, vol. 21, no. 1, pp. 96–105, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Saddadi, I. Najafi, M. S. Hakemi, K. Falaknazi, F. Attari, and B. Bahar, “Frequency, risk factors, and outcome of acute kidney injury following bone marrow transplantation at Dr Shariati Hospital in Tehran,” Iranian Journal of Kidney Diseases, vol. 4, no. 1, pp. 20–26, 2010. View at Google Scholar · View at Scopus
  3. A. Kogon and S. Hingorani, “Acute kidney injury in hematopoietic cell transplantation,” Seminars in Nephrology, vol. 30, no. 6, pp. 615–626, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Clajus, N. Hanke, J. Gottlieb et al., “Renal comorbidity after solid organ and stem cell transplantation,” American Journal of Transplantation, vol. 12, no. 7, pp. 1691–1699, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Liu, Y.-F. Li, B.-C. Liu et al., “A multicenter, retrospective study of acute kidney injury in adult patients with nonmyeloablative hematopoietic SCT,” Bone Marrow Transplantation, vol. 45, no. 1, pp. 153–158, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Ando, J. Mori, K. Ohashi et al., “A comparative assessment of the RIFLE, AKIN and conventional criteria for acute kidney injury after hematopoietic SCT,” Bone Marrow Transplantation, vol. 45, no. 9, pp. 1427–1434, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. Z.-P. Yu, J.-H. Ding, B.-A. Chen et al., “Risk factors for acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation,” Chinese Journal of Cancer, vol. 29, no. 11, pp. 946–951, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. J. L. Piñana, D. Valcárcel, R. Martino et al., “Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience,” Biology of Blood and Marrow Transplantation, vol. 15, no. 1, pp. 21–29, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Hingorani, L. S. Finn, E. Pao et al., “Urinary elafin and kidney injury in hematopoietic cell transplant recipients,” Clinical Journal of the American Society of Nephrology, vol. 10, no. 1, pp. 12–20, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Mori, K. Ohashi, T. Yamaguchi et al., “Risk assessment for acute kidney injury after allogeneic hematopoietic stem cell transplantation based on acute kidney injury network criteria,” Internal Medicine, vol. 51, no. 16, pp. 2105–2110, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Kagoya, K. Kataoka, Y. Nannya, and M. Kurokawacorrespondence, “Pretransplant predictors and posttransplant sequels of acute kidney injury after allogeneic stem cell transplantation,” Biology of Blood and Marrow Transplantation, vol. 17, no. 3, pp. 394–400, 2011. View at Publisher · View at Google Scholar
  12. J. A. Lopes and S. Jorge, “Acute kidney injury following HCT: incidence, risk factors and outcome,” Bone Marrow Transplantation, vol. 46, no. 11, pp. 1399–1408, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. S. H. Kang, H. S. Park, I. O. Sun et al., “Changes in renal function in long-term survivors of allogeneic hematopoietic stem-cell transplantation: single-center experience,” Clinical Nephrology, vol. 77, no. 3, pp. 225–230, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Caliskan, S. K. Besisik, D. Sargin, and T. Ecder, “Early renal injury after myeloablative allogeneic and autologous hematopoietic cell transplantation,” Bone Marrow Transplantation, vol. 38, no. 2, pp. 141–147, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Zhou, X.-N. Cen, Z.-X. Qiu et al., “Clinical analysis of acute renal failure after allogeneic hematopoietic stem cell transplantation,” Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol. 17, no. 3, pp. 723–728, 2009. View at Google Scholar · View at Scopus
  16. J. A. Lopes, S. Jorge, S. Silva et al., “Acute renal failure following myeloablative autologous and allogeneic hematopoietic cell transplantation,” Bone Marrow Transplantation, vol. 38, no. 10, p. 707, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Bellomo, C. Ronco, J. A. Kellum, R. L. Mehta, and P. Palevsky, “Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group,” Critical Care, vol. 8, no. 4, pp. R204–R212, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. R. L. Mehta, J. A. Kellum, S. V. Shah et al., “Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury,” Critical Care, vol. 11, no. 2, p. R31, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Ataei, M. Hadjibabaie, A. Moslehi et al., “A double-blind, randomized, controlled trial on N-acetylcysteine for the prevention of acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation,” Hematological Oncology, vol. 33, no. 2, pp. 67–74, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. J. A. Lopes, S. Gonçalves, S. Jorge et al., “Contemporary analysis of the influence of acute kidney injury after reduced intensity conditioning haematopoietic cell transplantation on long-term survival,” Bone Marrow Transplantation, vol. 42, no. 9, pp. 619–626, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. H. E. Wahlstrom, M. Lavelle-Jones, D. Endres, R. Akimoto, O. Kolterman, and A. R. Moossa, “Inhibition of insulin release by cyclosporine and production of peripheral insulin resistance in the dog,” Transplantation, vol. 49, no. 3, pp. 600–604, 1990. View at Google Scholar
  22. C. R. Parikh, B. M. Sandmaier, R. F. Storb et al., “Acute renal failure after nonmyeloablative hematopoietic cell transplantation,” Journal of the American Society of Nephrology, vol. 15, no. 7, pp. 1868–1876, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. R. W. Schrier and W. Wang, “Acute renal failure and sepsis,” The New England Journal of Medicine, vol. 351, no. 2, pp. 159–169, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Merouani, E. J. Shpall, R. B. Jones, P. G. Archer, and R. W. Schrier, “Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer,” Kidney International, vol. 50, no. 3, pp. 1026–1031, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Gruss, C. Bernis, J. F. Tomas et al., “Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome,” American Journal of Nephrology, vol. 15, no. 6, pp. 473–479, 1995. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Sorkine, H. Nagar, A. Weinbroum et al., “Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients,” Critical Care Medicine, vol. 24, no. 8, pp. 1311–1315, 1996. View at Publisher · View at Google Scholar · View at Scopus
  27. P. J. Cagnoni, “Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients,” Journal of Antimicrobial Chemotherapy, vol. 49, no. 1, pp. 81–86, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. S. R. Hingorani, K. Guthrie, A. Batchelder et al., “Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors,” Kidney International, vol. 67, no. 1, pp. 272–277, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. K. A. Marr, “Empirical antifungal therapy-new options, new tradeoffs,” New England Journal of Medicine, vol. 346, no. 4, pp. 278–280, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. P. N. Rocha, M. N. Macedo, C. D. Kobayashi et al., “Role of urine neutrophil gelatinase-associated lipocalin in the early diagnosis of amphotericin B-induced acute kidney injury,” Antimicrobial Agents and Chemotherapy, vol. 59, no. 11, pp. 6913–6921, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Brigden, A. E. Rosling, and N. C. Woods, “Renal function after acyclovir intravenous injection,” The American Journal of Medicine, vol. 73, no. 1, pp. 182–185, 1982. View at Publisher · View at Google Scholar · View at Scopus
  32. M. A. Perazella, “Crystal-induced acute renal failure,” The American Journal of Medicine, vol. 106, no. 4, pp. 459–465, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. M. H. Sawyer, D. E. Webb, J. E. Balow, and S. E. Straus, “Acyclovir-induced renal failure. Clinical course and histology,” The American Journal of Medicine, vol. 84, no. 6, pp. 1067–1071, 1988. View at Publisher · View at Google Scholar · View at Scopus
  34. K. M. Olsen, M. I. Rudis, J. A. Rebuck et al., “Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity,” Critical Care Medicine, vol. 32, no. 8, pp. 1678–1682, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. T. C. Bailey, J. Russell Little, B. Littenberg, R. M. Reichley, and W. Claiborne Dunagan, “A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides,” Clinical Infectious Diseases, vol. 24, no. 5, pp. 786–795, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. M. S. Stankowicz, J. Ibrahim, and D. L. Brown, “Once-daily aminoglycoside dosing: an update on current literature,” American Journal of Health-System Pharmacy, vol. 72, no. 16, pp. 1357–1364, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Raeisi, A. Ghorbanihaghjo, H. Argani et al., “The effects of valsartan on renal klotho expression and oxidative stress in alleviation of cyclosporine nephrotoxicity,” Transplantation, 2016. View at Publisher · View at Google Scholar
  38. E. Holler, H. J. Kolb, E. Hiller et al., “Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation,” Blood, vol. 73, no. 7, pp. 2018–2024, 1989. View at Google Scholar · View at Scopus
  39. H. Nakamae, T. Yamane, T. Hasegawa et al., “Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation,” American Journal of Hematology, vol. 81, no. 7, pp. 525–531, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. Á. Prókai, R. Csohány, E. Sziksz et al., “Calcineurin-inhibition results in upregulation of local renin and subsequent vascular endothelial growth factor production in renal collecting ducts,” Transplantation, vol. 100, no. 2, pp. 325–333, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. C. A. Gleissner, A. Doesch, P. Ehlermann et al., “Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy,” American Journal of Transplantation, vol. 6, no. 11, pp. 2750–2758, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. B. D. Humphreys, R. J. Soiffer, and C. C. Magee, “Renal failure associated with cancer and its treatment: an update,” Journal of the American Society of Nephrology, vol. 16, no. 1, pp. 151–161, 2005. View at Google Scholar
  43. J. A. Coppell, P. G. Richardson, R. Soiffer et al., “Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome,” Biology of Blood and Marrow Transplantation, vol. 16, no. 2, pp. 157–168, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. S. I. Bearman, “The syndrome of hepatic veno-occlusive disease after marrow transplantation,” Blood, vol. 85, no. 11, pp. 3005–3020, 1995. View at Google Scholar · View at Scopus
  45. L. D. DeLeve, X. Wang, G. C. Kanel et al., “Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome,” Hepatology, vol. 38, no. 4, pp. 900–908, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. I. S. Moiseev, E. V. Babenko, A. A. Sipol, V. N. Vavilov, and B. V. Afanasyev, “Measurement of circulating endothelial cells to support the diagnosis of veno-occlusive disease after hematopoietic stem cell transplantation,” International Journal of Laboratory Hematology, vol. 36, no. 4, pp. e27–e29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. C. Salat, E. Holler, H.-J. Kolb et al., “Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation,” Blood, vol. 89, no. 6, pp. 2184–2188, 1997. View at Google Scholar · View at Scopus
  48. M. Pihusch, H. Wegner, P. Goehring et al., “Diagnosis of hepatic veno-occlusive disease by plasminogen activator inhibitor-1 plasma antigen levels: a prospective analysis in 350 allogeneic hematopoietic stem cell recipients,” Transplantation, vol. 80, no. 10, pp. 1376–1382, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. P. G. Richardson, V. T. Ho, S. Giralt et al., “Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease,” Therapeutic Advances in Hematology, vol. 3, no. 4, pp. 253–265, 2012. View at Publisher · View at Google Scholar
  50. J. Qiao, J. Fu, T. Fang et al., “Evaluation of the effects of preconditioning regimens on hepatic veno-occlusive disease in mice after hematopoietic stem cell transplantation,” Experimental and Molecular Pathology, vol. 98, no. 1, pp. 73–78, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Gökce, B. Kuskonmaz, M. Cetin, D. U. Cetinkaya, and M. Tuncer, “Coexisting or underlying risk factors of hepatic veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients receiving prophylaxis,” Experimental and Clinical Transplantation, vol. 11, no. 5, pp. 440–446, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. G. B. McDonald, M. S. Hinds, L. D. Fisher et al., “Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients,” Annals of Internal Medicine, vol. 118, no. 4, pp. 255–267, 1993. View at Publisher · View at Google Scholar · View at Scopus
  53. R. J. Jones, K. S. K. Lee, W. E. Beschorner et al., “Venoocclusive disease of the liver following bone marrow transplantation,” Transplantation, vol. 44, no. 6, pp. 778–783, 1987. View at Publisher · View at Google Scholar · View at Scopus
  54. J.-H. Lee, S.-J. Choi, J.-H. Lee et al., “Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation,” Annals of Hematology, vol. 84, no. 5, pp. 321–330, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Cutler, K. Stevenson, H. T. Kim et al., “Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation,” Blood, vol. 112, no. 12, pp. 4425–4431, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. J.-H. Yoon, W.-S. Min, H.-J. Kim et al., “Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA?” Bone Marrow Transplantation, vol. 48, no. 12, pp. 1562–1568, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Mohty, F. Malard, M. Abecassis et al., “Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT),” Bone Marrow Transplantation, vol. 50, no. 6, pp. 781–789, 2015. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Park, H. J. Park, H.-S. Eom et al., “Safety and effects of prophylactic defibrotide for sinusoidal obstruction syndrome in hematopoietic stem cell transplantation,” Annals of Transplantation, vol. 18, no. 1, pp. 36–42, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. P. G. Richardson, M. L. Riches, N. A. Kernan et al., “Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure,” Blood, vol. 127, no. 13, pp. 1656–1665, 2016. View at Publisher · View at Google Scholar
  60. H. Takahashi, R. Sakai, A. Fujita et al., “Concentrated ascites reinfusion therapy for sinusoidal obstructive syndrome after hematopoietic stem cell transplantation,” Artificial Organs, vol. 37, no. 10, pp. 932–936, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. J. N. George, X. Li, J. R. McMinn, D. R. Terrell, S. K. Vesely, and G. B. Selby, “Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma,” Transfusion, vol. 44, no. 2, pp. 294–304, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Changsirikulchai, D. Myerson, K. A. Guthrie, G. B. McDonald, C. E. Alpers, and S. R. Hingorani, “Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 2, pp. 345–353, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. V. Eremina, J. A. Jefferson, J. Kowalewska et al., “VEGF inhibition and renal thrombotic microangiopathy,” The New England Journal of Medicine, vol. 358, no. 11, pp. 1129–1136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. C.-K. Min, S. Y. Kim, M. J. Lee et al., “Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation,” Bone Marrow Transplantation, vol. 38, no. 2, pp. 149–156, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. Ç. Ödek, T. Kendirli, A. Yaman, T. Ileri, Z. Kuloğlu, and E. Ince, “Cyclosporine-associated thrombotic microangiopathy and thrombocytopenia- associated multiple organ failure: a case successfully treated with therapeutic plasma exchange,” Journal of Pediatric Hematology/Oncology, vol. 36, no. 2, pp. e88–e90, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. A. Java, A. Edwards, A. Rossi et al., “Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature,” Transplant International, vol. 28, no. 9, pp. 1121–1125, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. E. Morales, C. Rabasco, E. Gutierrez, and M. Praga, “A case of thrombotic micro-angiopathy after heart transplantation successfully treated with eculizumab,” Transplant International, vol. 28, no. 7, pp. 878–880, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. Y. Arai, K. Yamashita, K. Mizugishi et al., “Serum neutrophil extracellular trap levels predict thrombotic microangiopathy after allogeneic stem cell transplantation,” Biology of Blood and Marrow Transplantation, vol. 19, no. 12, pp. 1683–1689, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. R. A. Zager, “Acute renal failure in the setting of bone marrow transplantation,” Kidney International, vol. 46, no. 5, pp. 1443–1458, 1994. View at Publisher · View at Google Scholar · View at Scopus
  70. D. M. Smith, D. D. Weisenburger, P. Bierman, A. Kessinger, W. P. Vaughan, and J. O. Armitage, “Acute renal failure associated with autologous bone marrow transplantation,” Bone Marrow Transplantation, vol. 2, no. 2, pp. 195–201, 1987. View at Google Scholar · View at Scopus
  71. R. A. Zager, “Studies of mechanisms and protective maneuvers in myoglobinuric acute renal injury,” Laboratory Investigation, vol. 60, no. 5, pp. 619–629, 1989. View at Google Scholar · View at Scopus
  72. R. A. Zager, C. Foerder, and C. Bredl, “The influence of mannitol on myoglobinuric acute renal failure: functional, biochemical, and morphological assessments,” Journal of the American Society of Nephrology, vol. 2, no. 4, pp. 848–855, 1991. View at Google Scholar · View at Scopus
  73. K. A. Blum, A. S. Ruppert, J. A. Woyach et al., “Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol,” Leukemia, vol. 25, no. 9, pp. 1444–1451, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. A. Q. Lam and B. D. Humphreys, “Onco-nephrology: AKI in the cancer patient,” Clinical Journal of the American Society of Nephrology, vol. 7, no. 10, pp. 1692–1700, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. T. I. Mughal, A. A. Ejaz, J. R. Foringer, and B. Coiffier, “An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome,” Cancer Treatment Reviews, vol. 36, no. 2, pp. 164–176, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Shimada, R. J. Johnson, W. S. May et al., “A novel role for uric acid in acute kidney injury associated with tumour lysis syndrome,” Nephrology Dialysis Transplantation, vol. 24, no. 10, pp. 2960–2964, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. H. H. Hirsch and J. Steiger, “Polyomavirus BK,” The Lancet Infectious Diseases, vol. 3, no. 10, pp. 611–623, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. K. L. Hardinger, M. J. Koch, D. J. Bohl, G. A. Storch, and D. C. Brennan, “BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results,” American Journal of Transplantation, vol. 10, no. 2, pp. 407–415, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Ito, N. Hirabayashi, Y. Uno, A. Nakayama, and J. Asai, “Necrotizing tubulointerstitial nephritis associated with adenovirus infection,” Human Pathology, vol. 22, no. 12, pp. 1225–1231, 1991. View at Publisher · View at Google Scholar · View at Scopus
  80. I. Bil-Lula, M. Ussowicz, B. Rybka et al., “Hematuria due to adenoviral infection in bone marrow transplant recipients,” Transplantation Proceedings, vol. 42, no. 9, pp. 3729–3734, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. B. Bruno, R. A. Zager, M. J. Boeckh et al., “Adenovirus nephritis in hematopoietic stem-cell transplantation,” Transplantation, vol. 77, no. 7, pp. 1049–1057, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. P. Fanourgiakis, A. Georgala, M. Vekemans et al., “Intravesical instillation of cidofovir in the treatment of hemorrhagic cystitis caused by adenovirus type 11 in a bone marrow transplant recipient,” Clinical Infectious Diseases, vol. 40, no. 1, pp. 199–201, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Sakurada, T. Kondo, M. Umeda, H. Kawabata, K. Yamashita, and A. Takaori-Kondo, “Successful treatment with intravesical cidofovir for virus-associated hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: a case report and a review of the literature,” Journal of Infection and Chemotherapy, vol. 22, no. 7, pp. 495–500, 2016. View at Publisher · View at Google Scholar
  84. S. R. Hingorani, K. Seidel, A. Lindner, T. Aneja, G. Schoch, and G. McDonald, “Albuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survival,” Biology of Blood and Marrow Transplantation, vol. 14, no. 12, pp. 1365–1372, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. N. Shingai, T. Morito, Y. Najima et al., “Urinary liver-type fatty acid-binding protein linked with increased risk of acute kidney injury after allogeneic stem cell transplantation,” Biology of Blood and Marrow Transplantation, vol. 20, no. 12, pp. 2010–2014, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. T. Morito, M. Ando, K. Tsuchiya, and K. Nitta, “Early identification of acute kidney injury after hematopoietic stem cell transplantation by the measurement of urinary biomarkers,” Nihon Jinzo Gakkai Shi, vol. 53, no. 8, pp. 1150–1158, 2011. View at Google Scholar · View at Scopus